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Research
Perfluorinated carboxylates (PFCAs) and 
per  fluorinated sulfonates (PFSAs) have been 
detected in human sera worldwide (Calafat 
et al. 2007; Haug et al. 2009; Kärrman et al. 
2006; Olsen et al. 2008). PFCA and PFSA 
human contamination are surprisingly similar 
in North America (Calafat et al. 2007; Olsen 
et al. 2008), Europe (Haug et al. 2009), and 
Australia (Kärrman et al. 2006), given the 
marked differences in environ  mental contami-
na  tion (Yamashita et al. 2005). Despite the 
ubiquity of PFCAs and PFSAs in human sera, 
major sources of this contamination are not 
well understood.
Fluorochemicals have historically been 
manufactured via two different processes. 
Electrochemical fluorination (ECF) was used 
in the production of perfluoro  octane sulfonyl 
fluoride [POSF; F(CF2)8SO2F], which was 
further functionalized into the sulfonamido 
ethanols. Telomerization was used in the pro-
duction of the fluoro  telomer alcohols [FTOHs; 
F(CF2)xCH2CH2OH]. These two alcohols 
were then used to manu  facture commercial 
surfactants and polymers. A major difference 
between these processes is that telomeriza  tion 
produces exclusively the linear isomer, whereas 
ECF produces fluoro  chemicals with a mixture 
of structural isomers (Kissa 2002).
A major shift in industrial fluoro  chemical 
production occurred in 2000, when 3M, the 
major manufacturer of the POSF-based chem-
istries, began phasing out its perfluoro  octyl 
materials (3M 2000). This change in produc-
tion was mirrored in human sera, as concentra-
tions of perfluoro  octane sulfonate (PFOS) and 
perfluoro  octanoate (PFOA) began to decrease 
around the year 2000 (Calafat et al. 2007; 
Haug et al. 2009; Olsen et al. 2008). These 
studies generally show a larger decrease in con-
centrations of PFOS compared with PFOA. 
PFOS has a longer human serum elimination 
half-life (Olsen et al. 2007), thus suggesting 
continued exposure to PFOA without similar 
exposure to PFOS. 
Consistent with continued exposure to 
PFOA, concentrations of the longer chain 
PFCAs—perfluoro  nonanoate (PFNA), per-
fluoro  decanoate (PFDA), and perfluoro-
undecanoate (PFUnA)—have continued to 
increase in human sera since the 2000 POSF 
phase-out (Calafat et al. 2007; Haug et al. 
2009). The most plausible explanation for 
continued PFCA exposure, without contin-
ued exposure to PFOS, is human exposure to 
fluorotelomer-based commercial materials.
Exposure to perfluorinated acids from the 
biotransformation of precursor materials is not 
a new idea. The sulfonamide-based materi-
als can be biotransformed to PFOS (Xu et al. 
2004), and acetate metabolites have frequently 
been detected in human sera (Calafat et al. 
2007; Haug et al. 2009; Olsen et al. 2008). 
Biotransformation from FTOH to PFCA 
has previously been observed in a rat model 
(Fasano et al. 2006; Hagen et al. 1981). 
Fluorotelomer-based materials are composed 
of a mixture of chain lengths (Kissa 2002), 
so biotransformation of these compounds 
could explain concurrent human exposure to 
PFCAs of several chain lengths. In addition, 
the PFCA isomer profile in human sera is sug-
gestive of a fluoro  telomer source, because it is 
almost entirely linear (De Silva and Mabury 
2006), with a diminished contribution from 
specific ECF isomers found to be more bio-
accumulative than the linear isomer (Benskin 
et al. 2009; De Silva et al. 2009).
One class of fluorotelomer-based com-
mercial products with a high potential for 
human exposure is the polyfluoro  alkyl phos-
phate esters (PAPs). Commercial PAP for-
mulations contain a mixture of fluorinated 
chain lengths as well as phosphate mono-, 
di-, and triesters (Begley et al. 2008; Kissa 
2002). By synthesizing individual conge-
ners in-house, we simplified this complex 
mixture to four PAP diesters [diPAPs; x:2,   
(OH)P(O)(OCH2CH2(CF2)xF)2, where x = 4, 
6, 8, or 10] and four PAP monoesters [mono-
PAPs; x:2, (OH)2P(O)(OCH2CH2(CF2)xF), 
where x = 4, 6, 8, or 10]. PAPs are used to 
grease  proof food-contact paper products and 
have a demon  strated ability to migrate from 
packaging into food (Begley et al. 2008). 
Biotransformation from PAP to PFCA has 
previously been observed in rats (D’eon and 
Mabury 2007) and in a microbial system (Lee 
et al. 2010). Human PAP exposure has also 
been confirmed by the detection of several 
diPAP congeners in human sera at micro-
gram per liter concentrations (D’eon et al. 
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Ba c k g r o u n d: Perfluorinated carboxylic acids (PFCAs) are ubiquitous in human sera worldwide. 
Biotransformation of the polyfluoroalkyl phosphate esters (PAPs) is a possible source of PFCA expo-
sure, because PAPs are used in food-contact paper packaging and have been observed in human sera.
oBjectives: We determined pharmacokinetic parameters for the PAP monoesters (monoPAPs) and 
PAP diesters (diPAPs), as well as biotransformation yields to the PFCAs, using a rat model.
Me t h o d s : The animals were dosed intravenously or by oral gavage with a mixture of 4:2, 6:2, 8:2, 
and 10:2 monoPAP or diPAP chain lengths. Concentrations of the PAPs and PFCAs, as well as meta-
bolic intermediates and phase II metabolites, were monitored over time in blood, urine, and feces.
re s u l t s: The diPAPs were bioavailable, with bioavailability decreasing as the chain length increased 
from 4 to 10 perfluorinated carbons. The monoPAPs were not absorbed from the gut; however, 
we found evidence to suggest phosphate-ester cleavage within the gut contents. We observed bio-
transformation to the PFCAs for both monoPAP and diPAP congeners.
co n c l u s i o n s: Using experimentally derived biotransformation yields, perfluoro  octanoic acid 
(PFOA) sera concentrations were predicted from the biotransformation of 8:2 diPAP at concentra-
tions observed in human serum. Because of the long human serum half-life of PFOA, biotrans-
formation of diPAP even with low-level exposure could over time result in significant exposure to 
PFOA. Although humans are exposed directly to PFCAs in food and dust, the pharmaco  kinetic 
parameters determined here suggest that PAP exposure should be considered a significant indirect 
source of human PFCA contamination.
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2009). The explicit hypothesis of this work is 
that PAP biotransformation contributes to the 
PFCA burden observed in human sera. We 
tested this hypothesis by determining PAP 
uptake, elimination, and biotransformation 
parameters to properly constrain PFCA pro-
duction from PAP exposure.
Materials and Methods
Chemical purchase, synthesis, and purity. 
PAPs were synthesized as described previously 
(D’eon and Mabury 2007), and diPAPs were 
purified by preparatory liquid chromatogra-
phy. We stripped monoPAPs of FTOHs by 
repeat dissolution in acetone, followed by sol-
vent evaporation under nitrogen [for details, 
see Supplemental Material (doi:10.1289/
ehp.1002409)].
Animal treatment. This research was 
conducted under an animal use proto-
col approved by the University of Toronto 
Animal Care Committee. All animals were 
treated humanely and with regard for alle-
viation of suffering. Sprague-Dawley rats were 
obtained from Charles River Laboratories 
Inc. (Sherbrooke, QC, Canada) The animals 
were singly housed and exposed to a 12/12 hr 
light/dark cycle with food and water avail-
able ad libitum. Blood samples were collected 
from the saphenous vein using Microvette CB 
300 vials (Sarstedt AG & Co., Montreal, QC, 
Canada) embedded with lithium-heparin as 
an anticoagulant. Whole-blood samples were 
stored at –20°C, and urine and feces samples 
were stored at 4°C.
Uptake experiment. Two groups of four 
8-week-old male rats were administered 
a mixture of 4:2, 6:2, 8:2, and 10:2 diPAP 
or monoPAP, respectively, each at about 50   
mg/kg, at 4 mL/kg by oral gavage without 
prior fasting. Because the diPAPs have demon-
strated solubility in emulsions (Begley et al. 
2008), the dosing vehicle used was 50:50 pro-
pylene glycol:water, with 0.1% soy lecithin 
added as an emulsifier. Two control male rats 
were administered clean vehicle at 4 mL/kg 
[for details, see Supplemental Material, Table 3 
(doi:10.1289/ehp.1002409)].
Elimination experiment. Two groups of 
four 8-week-old male rats were adminis  tered 
a mixture of 4:2, 6:2, 8:2, and 10:2 diPAP 
or monoPAP, respectively, each at about 
15 mg/kg, at 2 mL/kg by intravenous (IV) 
injection into the lateral tail vein. The dos-
ing vehicle was 50:50 propylene glycol:water. 
Two control male rats were adminis  tered 
clean vehicle at 2 mL/kg [for details see 
Supplemental Material, Table 3 (doi:10.1289/
ehp.1002409)].
Blood collection. Blood was collected from 
all animals 3 days before dosing to establish 
background contamination. For the uptake 
experiment, blood samples were collected 
at 1, 3, and 6 hr and 1, 2, 4, 7, 10, 14, 18, 
and 22 days after dosing. For the elimination 
experi  ment, blood samples were collected at 2, 
4, and 6 hr and 1, 2, 4, 8, 11, 15, and 18 days 
after dosing. On the final sampling day, 
the animals were sacrificed by carbon diox-
ide asphyxiation, and about 10 mL of blood 
was collected by cardiac puncture into a BD 
Vacutainer embedded with lithium-heparin.
Urine and feces collection. For both experi-
ments the animals were placed in metabolic 
cages for 48 hr post  dosing, with urine and 
feces samples collected when available at 3, 6, 
9, 24, 34, and 48 hr post  dosing.
Toxic end points. No toxicity data are 
available in the open scientific literature for 
the PAPs. However, the PAP dosing concen-
trations used here were consistent with previ-
ous investigations (D’eon and Mabury 2007), 
where no toxicity was observed. One fatal-
ity occurred in the diPAP dose group during 
blood sampling for the uptake experi  ment, 
for unknown reasons. Two fatalities occurred 
during dose adminis  tration in the elimina-
tion experi  ment (one animal from each dose 
group). Complications related to the use of 
propylene glycol as a dosing vehicle was the 
suspected cause of the fatalities. No physical 
signs of stress were observed in the other ani-
mals at any time during either study.
Analytical details. The compounds of inter-
est fall into four categories: a) the diPAP and 
monoPAP parent compounds, b) the saturated 
and unsaturated fluoro  telomer carboxylic acid 
(FTCA and FTUCA) metabolic inter  mediates, 
c) the FTOH-sulfate and FTOH-glucuronide 
phase II metabolites, and d) the final PFCA 
biotransformation products [see Supplemental 
Material, Table 1 (doi:10.1289/ehp.1002409)]. 
We analyzed these compounds in whole blood, 
urine, and feces samples. For full analytical 
details, see Supplemental Material. All PFCAs, 
FTCAs, FTUCAs, and phase II metabo-
lites were quantified by internal calibration. 
Because internal standards were not available, 
monoPAPs and diPAPs were quantified by 
standard addition. We performed spike and 
recovery exper  ments to validate the extraction 
and quantification techniques used (for details, 
see Supplemental Material). 
Data analysis. Analyte and matrix specific 
limits of detection (LODs) and limits of quan-
tification (LOQs) are provided in Supplemental 
Material (doi:10.1289/ehp.1002409). For the 
purpose of calculating means, values < LOD 
were assigned a value of zero, and values < LOQ 
but > LOD were used unaltered but are indi-
cated by asterisks in figures and parentheses 
in tables. Values are presented using the arith-
metic mean ± SE. Full data sets are available in 
Supplemental Material.
We included one procedural blank with 
the extraction of each time point. The only 
analyte observed in the procedural blanks 
or the control animals was PFOA; however, 
the observed contamination was consistently 
< LOQ and considered negligible.
For details regarding the calculation of 
pharmaco  kinetic parameters, see Supplemental 
Material (doi:10.1289/ehp.1002409).
Despite the rigorous purity analyses per-
formed, the diPAP IV dose was inadvertently 
contaminated with perfluoro  hexanoic acid 
(PFHxA). Because of the short serum half-life 
of PFHxA in male rats, this contamination 
was quickly eliminated (Ohmori et al. 2003). 
For clarity, the first three PFHxA time points 
(2–6 hr) from the diPAP IV experiment are not 
included in Figure 1. For full PFHxA concen-
trations from this experiment, see Supplemental 
Material (doi:10.1289/ehp.1002409).
In the present study and our previous inves-
tigations, diPAP identi  fi  ca  tion has involved 
two multiple reaction monitoring (MRM) 
transitions, one to the monoPAP and the other 
to [H2PO4]– (97 m/z) (D’eon et al. 2009; 
D’eon and Mabury 2007). In our previous 
biotransforma  tion study (D’eon and Mabury 
2007), only the MRM transition to [H2PO4]– 
was monitored for 8:2 monoPAP. From an in-
house synthesized 8:2 FTOH-sulfate standard, 
we recog  nized that the MRM transition of this 
species was indistinguishable from that of 8:2 
monoPAP (543 m/z > 97 m/z). This potential 
interference was resolved in the present study 
by adding an additional MRM transition to 
[PO3]– (79 m/z) for monoPAP quantification, 
as well as chromatographically separating the 
FTOH-sulfates and monoPAPs.
Results
Absorption of 8:2 monoPAP and 8:2 diPAP, as 
well as biotransformation to PFOA, has previ-
ously been observed in rats (D’eon and Mabury 
2007). Our hypothesis that PAPs may contrib-
ute to the burden of PFCAs observed in human 
sera was supported by the observation of diPAPs 
at microgram per liter concentrations in human 
sera from the United States (D’eon et al. 2009). 
To properly constrain PFCA production from 
PAP exposure, in the present study we under-
took an in-depth evaluation of PAP uptake, 
elimination, and biotransformation. 
Uptake. We calculated percent bioavail-
ability using the area under the curve after 
gavage and IV dose administration (AUCgavage 
and AUCiv, respectively), normalized to the 
concentration of the respective doses: 
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Figure 1 shows diPAP concentration–time plots 
after gavage and IV dosing. Bioavailabilities 
determined using Equation 1 were 190%, 
74%, and 5% for 4:2, 6:2, and 8:2 diPAP con-
geners, respectively (10:2 diPAP was < LOD  D’eon and Mabury
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in the gavage experiment). Because a bioavail-
ability > 100% is not possible, diPAP bioavail-
ability may be over  estimated.
We collected the first blood sample 2 hr 
after IV dose administration; in retrospect, 
there could have been an initial excretion phase 
that was not properly captured. Conversely, 
toxicological complications with the IV dose 
could also be responsible for this apparent dis-
crepancy. In the absence of any confounding 
factors, it is possible that there was a physio-
logical cause for the percent bioavailability 
> 100%. Ward et al. (2004) observed the same 
phenomenon for the drug SB-265123, an 
organic carboxylate, and implicated saturable 
intestinal secretory transport proteins in the 
over  estimation of the compound’s bioavail-
ability. Fecal excretion after diPAP IV dosing 
was greatest for 6:2 diPAP (see “Fecal elimina-
tion”), a trend that may suggest active elimina-
tion. Organic anion transport proteins have 
been implicated in the renal control of the 
PFCAs (Andersen et al. 2008) and may also 
be involved in the uptake of PFOA into rat 
hepato  cytes (Han et al. 2008). Therefore, it 
is possible that similar transport proteins may 
be involved in the movement of fluorinated 
acids, including the diPAPs, between the gut 
contents and the bloodstream.
We observed no monoPAP congeners 
in the blood of the dosed animals in the 
present study. Because this study was designed 
to investigate PAP kinetics in the blood, it is 
not possible to determine if the monoPAPs 
partitioned into other compartments within 
the body. Further mass balance studies are 
warranted to fully charac  terize the fate of these 
chemicals in the body.
The lack of monoPAPs we observed 
in the blood contrasts results of a previous 
study (D’eon and Mabury 2007), in which 
we observed 8:2 monoPAP concentrations 
> 100 ng/g after oral gavage at 200 mg/kg. 
As described in “Material and Methods,” it is 
possible that in the previous study we over-
estimated the oral absorption of 8:2 mono-
PAP because of interference from the phase II 
metabolite 8:2 FTOH-sulfate.
Elimination kinetics in the blood. We deter-
mined elimination half-lives from whole blood 
for the diPAP congeners after both the gavage 
and IV dosing (Table 1). Half-lives after IV 
dosing (mean ± SE) were 1.6 ± 0.1, 2.1 ± 0.3, 
4.8 ± 1.0, and 3.3 ± 0.4 days for 4:2, 6:2, 8:2, 
and 10:2 diPAP, respectively. Half-lives after 
oral gavage dosing were 2.0 ± 0.1, 3.9 ± 0.7, 
and 2.4 ± 0.2 days for 4:2, 6:2, and 8:2 diPAP, 
respectively. We did not observe 10:2 diPAP 
in the blood of the animals from the gavage 
experiment, so no half-life could be calculated. 
As expected, the diPAP half-lives generally 
increased with increasing diPAP chain length.
Half-lives were recently determined for 
the di-substituted perfluoroalkyl phosphinic 
acids (diPFPAs) in both male and female rats 
(D’eon and Mabury 2010). The diPFPAs are 
structurally similar to the diPAPs, except their 
alkyl chains are fully fluorinated and bound 
directly to the phosphorus center. Half-lives of 
the diPFPAs in male rats after intraperitoneal 
injection ranged from 1.8 to 5.4 days. These 
half-lives are similar to those observed here for 
the diPAPs.
Renal elimination. We did not observe 
the monoPAPs in urine after IV or gavage 
dosing. This may result from low renal elimi-
nation or their inability to reach the kidneys 
through the blood.
The only diPAP congener we observed in 
urine was 4:2 diPAP. However, renal elimina-
tion is unlikely to be the major route of 4:2 
diPAP elimination because the levels observed 
could account for only 0.03% of the adminis-
tered gavage dose, and we detected 4:2 diPAP 
only sporadically in urine samples after IV 
dosing. This result is consistent with the low 
renal elimination observed for the longer 
chain PFCA, PFDA (Ohmori et al. 2003).
The shorter chain PFCAs (≤ C8), as well 
as 4:2 FTOH-glucuronide and 4:2 FTOH-
sulfate, were consistently observed in the urine 
samples from all dosing regimes (for full data 
sets, see Supplemental Material, Tables 25–30 
(doi:10.1289/ehp.1002409)].
Fecal elimination. We did not observe 
the monoPAPs in fecal samples collected after 
IV dosing. This may result from low mono-
PAP fecal elimina  tion or their partitioning 
to tissues other than the liver, where biliary 
excretion is possible. Conversely, 6:2, 8:2, and 
10:2 monoPAPs were present in feces collected 
24 hr after gavage dosing at levels that account 
for about 1% of the adminis  tered gavage dose. 
[We encountered analytical challenges with 
the extraction and analysis of 4:2 monoPAP in 
the fecal samples; for details, see Supplemental 
Material (doi:10.1289/ehp.1002409).] Because 
the monoPAPs present in feces after gavage 
dosing likely resulted from residual dose, the 
low concentrations observed suggest that the 
monoPAPs either are taken up by the gut or 
are transformed within the gut contents.
We observed diPAPs in fecal samples 
after both IV and gavage dosing, so delineat-
ing residual dose from contributions from 
fecal excretion was not possible. Forty-eight 
hours after IV dosing, fecal elimination could 
account for 3%, 9%, 1%, and 0.04% of 4:2, 
6:2, 8:2, and 10:2 diPAP, respectively; how-
ever, 48 hr after gavage dosing, fecal elimina-
tion was higher: 21%, 65%, and 34% for 4:2, 
6:2, and 8:2 diPAP, respectively. 
We detected no biotransformation 
products in the feces [for full data sets, see 
Supplemental Material, Table 31 (doi:10.1289/
ehp.1002409)].
Figure 1. Arithmetic mean ± SE for the concentrations of the diPAP parent compounds and their expected 
primary PFCA biotransformation products observed in rats (n = 3) after diPAP dose administered either IV 
or via oral gavage. Values < LOD were assigned a value of zero; values < LOQ but > LOD are indicated by 
an asterisk [for full data sets, see Supplemental Material (doi:10.1289/ehp.1002409)]. Note that the diPAPs 
were dosed as a mixture; for clarity, the PFCA biotransformation products are plotted together with the 
expected parent diPAP. 
100,000
10,000
1,000
100
10
1
0.1
1,000
100
10
1
1,000
100
10
1
1,000
100
10
1
1,000
100
10
1
100,000
10,000
1,000
100
10
1
0.1
10,000
1,000
100
10
1
0.1
10,000
1,000
100
10
1
0.1
01 0
4:2 diPAP
gavage
8:2 diPAP
gavage
10:2 diPAP
gavage
10:2 diPAP
IV
8:2 diPAP
IV
6:2 diPAP
gavage
6:2 diPAP
IV
4:2 diPAP
IV
20 15
4:2 diPAP
PFBA (C4 PFCA)
PFPeA (C5 PFCA)
6:2 diPAP
PFHxA (C6 PFCA)
PFHpA (C7 PFCA)
8:2 diPAP
PFOA (C8 PFCA)
PFNA (C9 PFCA)
10:2 diPAP
PFDA (C10 PFCA)
PFUnA (C11 PFCA)
25 5
*
*
*
*
*
* *
* *
* * * *
* *
* * *
*
*
* *
*
* *
* *
*
*
*
01 02 0 15 25 50 10 20 15 25 50 10 20 15 25 5
01 02 0 15 25 50 10 20 15 25 50 10 20 15 25 50 10 20 15 25 5
Time (days)T ime (days)T ime (days)T ime (days)
Time (days)T ime (days)T ime (days)T ime (days)
C
o
n
c
e
n
t
r
a
t
i
o
n
 
i
n
 
b
l
o
o
d
 
(
n
g
/
g
)
C
o
n
c
e
n
t
r
a
t
i
o
n
 
i
n
 
b
l
o
o
d
 
(
n
g
/
g
)Pharmacokinetics of the polyfluoroalkyl phosphates
Environmental Health Perspectives  •  v o l u m e  119 | n u m b e r 3 | March 2011  347
Biotransformation. As reported previ-
ously in rats (D’eon and Mabury 2007) and 
in a microbial system (Lee et al. 2010), PAP 
biotransformation is expected to proceed via 
enzyme-mediated hydrolysis of the phosphate 
ester linkage, yielding the corresponding 
FTOH, which is then available for oxidation 
(Figure 2). 
The β-oxidation product is the major 
PFCA produced from FTOH oxidation (i.e., 
8:2 FTOH to PFOA), with minor produc-
tion of the α-oxidation product (i.e., 8:2 
FTOH to PFNA) and shorter chain PFCAs 
(Fasano et al. 2006; Hagen et al. 1981). The 
concentration of PFCA products we observed 
in the blood of dosed animals is dependent 
on both bio  trans  formation yields and PFCA 
pharmaco  kinetics. Generally, the PFCA con-
gener profile present in the blood of both 
the diPAP- and monoPAP-dosed animals 
agreed with the expected bio  transformation 
pathway, with elevated levels of the even-
chain-length PFCAs compared with the odd-
chain-length congeners [Table 1; for full data 
sets, see Supplemental Material (doi:10.1289/
ehp.1002409)]. Concentrations of the 
PFCA products observed in the blood of the 
diPAP-dosed animals are plotted with their 
expected diPAP parent in Figure 1. Although 
we did not observe monoPAPs in the blood 
of the dosed animals, we did observe PFCA 
biotransformation products after monoPAP 
dosing (Table 1).
We also monitored metabolic inter-
mediates and phase II metabolites in the 
blood of the dosed animals [for full data sets, 
see Supplemental Material (doi:10.1289/
ehp.1002409)]. The highest concentrations of 
metabolic intermediates and phase II metab-
olites were observed after monoPAP oral 
gavage. We frequently detected 6:2 FTCA, 
6:2 FTUCA, 8:2 FTCA, and 8:2 FTUCA 
in blood samples taken 2, 4, and 6 hr post-
dosing. Both 5:3 and 7:3 FTCA were present 
in all of the samples from 2 hr to 2 days post-
dosing. The 4:2 and 6:2 FTOH-glucuronides 
were observed at 2 hr and 6 hr post  dosing, 
and the 8:2 and 10:2 FTOH-sulfates were 
frequently detected between 6 hr and 2 days 
post  dosing. After monoPAP IV dosing, we 
detected 4:2 FTCA, 4:2 FTUCA, and 6:2 
FTCA 2 hr post  dosing; 6:2 FTUCA and 5:3 
FTCA were observed in the 2, 4, and 6-hr 
time points. We also detected 4:2 FTOH-
sulfate and 4:2 FTOH-glucuronide in the 
blood 2 hr after dosing.
After diPAP dosing, we detected meta-
bolic intermediates and phase II metabo  lites 
only sporadically. After diPAP oral gavage, 
10:2 FTCA was present in the blood at the 
6-hr time point. We also observed 4:2 FTCA, 
4:2 FTUCA, 6:2 FTCA, 6:2 FTUCA, and 
8:2 FTCA 6 hr post  dosing, but in only one 
animal. The only phase II metabolite observed 
was 10:2 FTOH-sulfate at 1 and 2 days after 
dosing. After IV diPAP dosing, we observed 
5:3 FTCA in the samples from 2 hr to 2 days 
post  dosing and 10:2 FTCA only in the sam-
ple collected 2 days after dosing. We also 
detected 4:2 FTOH-sulfate and 4:2 FTOH-
glucuronide in the blood 2 hr post  dosing. No 
monoPAPs were observed in the blood of any 
diPAP-dosed animal.
Discussion
Migration from paper packaging into food is 
likely the major route of human PAP exposure. 
Table 1. Pharmacokinetic parameters for the diPAPs and PFCA biotransformation products determined from analyte concentrations in whole blood.
Gavage dose IV dose
Acronym Bioavailability (%) Biotransformationa (%) Half-life (days) Tmax Cmax (ng/g) Biotransformationa (%) Half-life (days) Tmax Cmax (ng/g)
diPAP dose
4:2 diPAP 190 0.005 2.0 ± 0.1 6 hr 39,000 ± 4,000 0.5 1.6 ± 0.1 2 hr 14,000 ± 1,000
6:2 diPAP 74 0.6 3.9 ± 0.7 4 hr 1,500 ± 500 1 2.1 ± 0.3 2 hr 2,200 ± 200
8:2 diPAP 5 9 2.4 ± 0.3 1 day 400 ± 60 9 4.8 ± 1.0 1 day 490 ± 120
10:2 diPAP NAb NAb NAb NA ND 8 3.3 ± 0.4 1 day 480 ± 110
PFBA — — NAc 1 day 3.8 ± 1.0 — 3.3 ± 1.2 1 day 20 ± 5
PFPeA — — — NA ND — — 2 hr 7.1 ± 0.6
PFHxA — — 4.2 ± 1.3 4 hr 10 ± 1.2 — 1.8 ± 0.51 1 day (3.0 ± 1.0)d
PFHpA — — — 1 day 2.6 ± 0.5 — — 4 hr 7.3 ± 0.6
PFOA — — 11 ± 2 4 days 7.2 ± 1.7 — 23 ± 17 2 days 9.3 ± 2.4
PFNA — — — 8 days 6.4 ± 5.2 — — 15 days (4.1 ± 3.3)
PFDA — — 11 ± 2 1 day 3.6 ± 0.6 — 10 ± 2 2 days 6.2 ± 1.2
PFUnA — — — NA ND — — NA ND
monoPAP dose
PFBA — — NAc 1 day 9.7 ± 1.9 — 0.53 ± 0.15 6 hr 7.3 ± 1.3
PFPeA — — — NA ND — — 6 hr 2.1 ± 0.8
PFHxA — — NA3 4 hr 7.4 ± 1.5 — 0.23 ± 0.23 4 hr 5.6 ± 1.3
PFHpA — — — 1 day 9.0 ± 2.2 — — 1 day 2.3 ± 0.7
PFOA — — 10 ± 2 1 day 28 ± 8 — 12 ± 6 4 days 8.5 ± 1.4
PFNA — — — 1 day (1.5 ± 0.09) — — 15 days 2.3 ± 0.4
PFDA — — 12 ± 8 2 days (1.1 ± 0.27) — 13 ± 9 15 days 0.93 ± 0.20
PFUnA — — — NA ND — — NA ND
Abbreviations: —, not relevant; Cmax, maximum concentration; NA, not available; ND, not detected; PFHpA, perfluoroheptanoic acid; PFPeA, perfluoropentanoic acid; Tmax, time of 
maximal concentration. monoPAP is not included because it was not found in any blood sample. Values < LOD were assigned a value of zero; values < LOQ but > LOD are shown in 
parentheses. For full data sets, including concentrations of metabolic intermediates and phase II metabolites, see Supplemental Material, Tables 13–24 (doi:10.1289/ehp.1002409). 
aBiotransformation was calculated using Equation 2. b10:2 diPAP was not observed in the blood after diPAP gavage dosing, so no parameters that require these concentrations could 
be calculated. cBecause the excretion phase was not properly captured, no half-life could be calculated for PFBA after diPAP gavage dosing, or for PFBA and PFHxA after monoPAP 
gavage dosing. dThe first three PFHxA time points after diPAP intravenous dosing were omitted because of inadvertent PFHxA contamination of the dose, as described in the text. 
Figure 2. Biotransformation of x:2 monoPAP (A) and x:2 diPAP (B).
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Therefore, understanding bioavailability is 
important to properly charac  terize exposure. 
With observed bioavailabilities of 190%, 74%, 
and 5% for 4:2, 6:2, and 8:2 diPAP conge-
ners, respectively, aside from potential over-
estimation, it is clear that in the present study 
the diPAP congeners were absorbed from the 
gut contents into the bloodstream. There is 
also a clear decreasing trend in bioavailability 
as chain length increases from C4 to C8 per-
fluorinated carbons.
Telomerization inherently produces a mix-
ture of perfluoro  alkyl chain lengths (Kissa 
2002), and in the manufacture of fluoro-
telomer surfactants this process is optimized 
to produce predominantly the perfluoro-
hexyl chain length (Dupont 2002). We pre-
viously found the diPAP congener profile in 
human sera to be dominated by 6:2 diPAP 
(D’eon et al. 2009). Increased exposure to the 
perfluoro  hexyl chain length, combined with 
increased bio  availability of the shorter chain 
lengths, is consistent with the higher concen-
trations of 6:2 diPAP observed in human sera.
Interest in human diPAP exposure is 
related both to the diPAPs themselves and 
to their potential contribution to human 
PFCA contamination. We observed PFCA 
biotrans  formation products in the blood of 
the diPAP-dosed animals, which are plotted 
together with their expected diPAP parent 
in Figure 1. Despite the observation of rela-
tively high PFCA concentrations, we detected 
metabolic intermediates only intermittently 
[see Supplemental Material (doi:10.1289/
ehp.1002409)]. This result was surprising 
because it contrasts the high concentrations 
of 8:2 FTCA observed after 8:2 FTOH gavage 
in the rat (Fasano et al. 2006). FTOHs are the 
direct product of diPAP hydrolysis [as shown 
in Figure 2B; (D’eon and Mabury 2007; Lee 
et al. 2010)]. Disparity between concentra-
tions of metabo  lic inter  mediates observed 
after diPAP dosing, compared with FTOH 
  dosing, demon  strates that diPAP exposure 
does not simply mimic FTOH exposure. The 
low concentrations of metabolic intermediates 
observed after diPAP exposure may explain 
why, in contrast to the frequent detection of 
sulfonamide oxidation products (Calafat et al. 
2007; Haug et al. 2009; Olsen et al. 2008), 
intermediates in the biotrans  formation of fluo-
rotelomer   materials have never been reported 
in human sera.
Contrary to the observations after diPAP 
exposure, we did not observe monoPAPs in 
the blood of the monoPAP-dosed animals. 
However, we observed 6:2, 8:2, and 10:2 
monoPAPs in feces samples collected in the 
first 24 hr after administration of the mono-
PAP gavage dose. Because we did not detect 
monoPAPs in the feces after IV dosing, the 
concentrations observed after oral gavage pre-
sumably result from residual dosing material. 
The mass of monoPAPs recovered in the feces 
after oral gavage could account for < 1% of 
the adminis  tered gavage dose, indicating that 
the monoPAPs did not pass through the gut 
unaltered but were either absorbed from the 
gut or bio  transformed within the gut con-
tents. It is difficult to delineate between these 
two possibilities; however, there is literature 
precedent for enzyme-mediated hydrolysis 
within the gut contents, because this has been 
observed in biotransformation studies of 8:2 
fluorotelomer acrylate in rainbow trout (Butt 
et al. 2010).
Despite the lack of monoPAPs observed 
in the blood, we consistently detected PFCA 
biotransformation products in the monoPAP-
dosed animals (Table 1). We also detected 
relatively high concentrations of several meta-
bolic intermediates, a result that is similar to 
previous studies involving FTOH exposure in 
the rat (Fasano et al. 2006). This consistency 
between monoPAP and FTOH exposure sup-
ports the hypothesis that monoPAP phosphate 
ester hydrolysis occurs within the gut contents, 
followed by FTOH uptake and further oxida-
tion, because this route of exposure would 
essentially mimic direct FTOH exposure.
Differences between diPAP and monoPAP 
exposure were not limited to relative concentra-
tions of metabolic intermediates. Elimination 
kinetics of the short-chain PFCA products in 
the blood [perfluoro  butanoic acid (PFBA) and 
PFHxA] were significantly slower after diPAP 
dose adminis  tration than after monoPAP 
(t-test, p < 0.01; Table 1). After diPAP IV dos-
ing, we observed serum elimination half-lives 
of 3.3 ± 1.2 days and 1.8 ± 0.5 days for PFBA 
and PFHxA, respectively, whereas after mono-
PAP IV dosing the observed half-lives were 
0.53 ± 0.15 days and 0.23 ± 0.23 days, respec-
tively. We observed a similarly long half-life 
for PFHxA after diPAP oral gavage (4.2 ± 1.3 
days). PFBA and PFHxA have serum half-lives 
on the order of hours in male rats (Chang et al. 
2008; Ohmori et al. 2003); the longer serum 
half-lives we observed after diPAP dose admin-
istration suggest a continual source of these 
compounds to the animal after the initial bolus 
dose. This observation is consistent with the 
gradual biotransformation of diPAP congeners 
present within the body. Conversely, similar-
ity between PFBA and PFHxA elimination 
half-lives in the literature (Chang et al. 2008; 
Ohmori et al. 2003) and those observed after 
bolus monoPAP exposure supports the hypoth-
esis that most monoPAP biotransformation 
occurred at the time of dose adminis  tration.
If most of the observed diPAP biotrans-
formation occurred within the body, then we 
can potentially use diPAP concentrations in the 
blood to predict the resulting PFCA burden. 
Percent biotransformation will be predicted 
for the diPAP congeners using the AUC for 
both the parent diPAP and product PFCA after 
either IV or oral gavage dose administration 
using Equation 2: 
.
Percentb iotransformation
2
1
AUCx2d iPAP
AUCC xP FCA
100
Gavage or IV
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# #
=
: ^
^
h
h  
[2]
Because this calculation involves conversion 
between two chemical species, it was per-
formed using blood concentrations expressed 
in moles as opposed to mass [see Supplemental 
Material (doi:10.1289/ehp.1002409)]. These 
biotransformation yields should be considered 
conservative because they assume the produc-
tion of 2 mol PFCA from 1 mol diPAP.
Applying this definition of percent bio-
transformation to the diPAP experiments 
resulted in < 1% biotransformation for 4:2 
diPAP, with this increasing to about 1% for 
6:2 diPAP and to about 10% for 8:2 and 10:2 
diPAP (Table 1). These percentages do not 
represent ratios of parent to product con-
centrations observed in the blood. Instead, 
they describe the cumulative PFCA burden 
imparted to the animal from the cumulative 
diPAP exposure observed in the blood. These 
predictions are species specific because they are 
heavily dependent on the pharmaco  kinetics of 
both parent and product. Pharmacokinetic 
parameters for fluorinated acids are not easily 
scaled between species (Andersen et al. 2008), 
so caution must be used when comparing 
predictions made in the rat with situations in 
other species, including humans.
Comparison between contaminant tem-
poral trends in human sera with chemical 
production can delineate between exposures 
to current-use materials and legacy chemical 
use. For both PFOS and PFOA, a concurrent 
decline in the levels of these contaminants in 
human sera has been reported with the phase-
out of the POSF-based materials (PFOA tem-
poral trend shown in Figure 3B) (Calafat et al. 
2007; Haug et al. 2009; Olsen et al. 2008). 
This trend suggests that POSF production was 
intimately linked to human PFOS and PFOA 
exposure. The correlation between POSF pro-
duction and the PFOS found in human sera is 
clear, because PFOS can be produced from the 
biotransformation of the sulfonamide com-
mercial materials (Xu et al. 2004), and sulfon-
amide oxidation products have been observed 
in human sera (Calafat et al. 2007; Haug et al. 
2009; Olsen et al. 2008). The correlation 
between POSF production and human PFOA 
contamination is not as clear. The issue is fur-
ther complicated by the observation that the 
decrease in PFOS concentrations was greater 
than that of PFOA (Calafat et al. 2007; Haug 
et al. 2009; Olsen et al. 2008), despite experi-
mental data indicating faster human serum 
elimination kinetics for PFOA than for PFOS 
(Olsen et al. 2007). The best explanation for 
this phenomenon is that the observed PFOA Pharmacokinetics of the polyfluoroalkyl phosphates
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elimination kinetics are offset by continued 
PFOA exposure. The same temporal trends 
also indicate continued exposure to PFNA, 
PFDA, and PFUnA (Calafat et al. 2007; Haug 
et al. 2009; Olsen et al. 2008). Although it is 
difficult to know whether changes in industrial 
practice by other fluoro  chemical producers 
may have also contributed to human PFOA 
exposure, the temporal trends in human sera 
are consistent with POSF-based materials 
being a significant source of human expo-
sure to PFOS and PFOA until 2000. After 
2000, fluoro  telomer production continued to 
increase (Figure 3A), and exposure to fluoro-
telomer-based materials may explain continued 
exposure to PFOA, together with increasing 
exposure to the longer chain PFCAs, such as 
PFNA, PFDA, and PFUnA.
A major limitation to understanding the 
connection between human fluoro  telomer 
exposure and PFCA contamination is the abil-
ity to constrain PFCA production from fluoro-
telomer biotransformation. A simple calculation 
using the biotransformation yields determined 
here may highlight the potential for fluoro-
telomer biotransformation to contribute to 
PFCA contamination. Human serum elimina-
tion of PFOA can be predicted using the arith-
metic human serum half-life of 4.5 years (Olsen 
et al. 2007). In Figure 3B, the blue line indi-
cates predicted elimination of PFOA, starting 
at 5 μg/L in the year 2000, without continued 
exposure. This prediction estimates PFOA con-
centrations slightly below the empirical obser-
vations. To predict PFOA exposure from 8:2 
diPAP biotransformation, we assumed a con-
stant concentration of 0.15 μg/L 8:2 diPAP in 
human serum from 2000 to 2020 (Figure 3B, 
black line). This serum concentration was based 
on 8:2 diPAP levels observed in human sera 
from the United States in 2008 (D’eon et al. 
2009). We then estimated PFOA production 
from 8:2 diPAP biotransformation by quantiz-
ing 8:2 diPAP exposure to 1-month intervals 
and calculating the expected increase in PFOA 
sera concentrations using a 10% biotransforma-
tion yield [Figure 3B, orange line; for details, 
see Supplemental Material (doi:10.1289/
ehp.1002409)]. Combining predicted PFOA 
depuration (Figure 3B, blue line) with contin-
ued PFOA exposure from 8:2 diPAP biotrans-
formation (Figure 3B, orange line) produces the 
purple line in Figure 3B, which better predicts 
the temporal trend of PFOA in human sera. 
This simple calculation demon  strates the ability 
of relatively low-level fluoro  telomer exposure 
to produce PFCA burdens similar to those cur-
rently observed in human sera.
Conclusion
Despite the ubiquity of human PFCA and 
PFSA contamination, major sources of this 
exposure are not fully appreciated. Attempts to 
model human exposure have generally focused 
on the PFSAs and PFCAs present in food 
items, household dust, and drinking water. 
These studies have consistently identified food 
as the major exposure pathway of those inves-
tigated (Fromme et al. 2007, 2009; Kärrman 
et al. 2009; Trudel et al. 2008; Vestergren et al. 
2008). PFCA and PFSA contamination of 
Canadian foodstuffs was unchanged between 
1998 and 2004 (Ostertag et al. 2009). Given 
the marked changes in fluoro  chemical pro-
duction during this time period (Figure 3A), 
this suggests that the contamination of food 
items results from legacy environmental con-
tamination (Vestergren and Cousins 2009). 
Consequently, food-borne exposure cannot 
explain the decrease in PFOS and PFOA levels 
observed in human serum in North America 
and Europe that began around the year 2000 
(Calafat et al. 2007; Haug et al. 2009; Olsen 
et al. 2008), in concert with changes in POSF 
production (3M 2000). Commercial fluoro-
chemical materials and formulations likely 
do mirror changes in production and market 
share. As a result, human exposure to com-
mercial materials may explain the concerted 
changes observed in human contamination 
with changes in fluoro  chemical production.
Some attempts have been made to model 
human PFCA and PFSA exposure via the 
biotransformation of fluoro  telomer and 
sulfonamide materials and have found this 
exposure source to be negligible (Fromme 
et al. 2009; Vestergren et al. 2008). However, 
these modeling studies are premature because 
they are limited by a paucity of data regarding 
concentrations in exposure media as well as 
a lack of agreement regarding biotransforma-
tion yields. In addition, both studies consid-
ered human exposure only to residual FTOHs 
and sulfonamides, and not exposure to the 
actual commercial materials, which represent 
the largest potential source of exposure. Using 
the diPAP commercial surfactants as an exam-
ple, the high concentrations observed in paper 
fiber samples (≤ 1,400 ng/g) and waste  water 
treatment plant sludge (≤ 860 ng/g) indicate 
that these fluoro  chemicals are likely present 
at high concentrations in the indoor environ-
ment (D’eon et al. 2009). In migration tests, 
Begley et al. (2008) observed migration of 
about 0.5 μg 8:2 diPAP/g butter, implying 
exposure to about 6 μg 8:2 diPAP for every 
tablespoon (15 mL) of butter consumed after 
contact with PAP-treated paper. These expo-
sure estimates demon  strate that exposure to 
commercial fluoro  chemicals cannot be ignored 
and must be better characterized to properly 
understand human PFCA contamination.
The present study was built on the 
implicit notion of Hagen et al. (1981) that 
human PFCA contamination results from 
the biotransformation of fluorotelomer-based 
materials. The calculations shown in Figure 3B 
oversimplify the issue of human PFCA expo-
sure. Nevertheless, they demon  strate that the 
low-level diPAP contamination observed in 
human sera could result in significant PFCA 
exposure, especially for PFCA congeners with 
human half-lives on the order of years (≥ C8) 
(Olsen et al. 2007). Exposure to PAPs may 
be a significant source of PFCA exposure, the 
degree to which is difficult to assess without 
proprietary data regarding the production 
and use of different fluorinated materials. It 
should also be noted that exposure to fluoro-
telomer-based materials is not limited to PAPs 
and could occur via other pathways such as 
Figure 3. Estimated production volumes (A; data from Dupont 2002, 2005; Vestergren and Cousins 2009) and PFOA concentrations observed in human serum (B; 
data from Calafat et al. 2007; Haug et al 2009; Olsen et al. 2005, 2008) for 1970–2020. In B, data are plotted with the estimated 8:2 diPAP concentration in human 
sera [assumed to be constant (0.15 μg/L) from 2000 to 2020], predicted PFOA concentrations in human sera from 8:2 diPAP biotransformation, predicted PFOA 
depuration without continued exposure, and predicted PFOA depuration with continued exposure from 8:2 diPAP biotransformation alone. 
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inhalation of volatile precursors (Shoeib et al. 
2005; Stock et al. 2004) or ingestion of other 
fluorotelomer-based surfactants (Begley et al. 
2008; Fromme et al. 2009). Overall, diPAP 
bioavailability and PFCA bio  trans  forma  tion 
products observed in the present study demon-
strate that exposure to PAPs could be a signifi-
cant contributor to the PFCA burden currently 
observed in humans.
RefeRences
3M. 2000. Phase-out Plan for POSF-Based Products. U.S. EPA 
(Environmental Protection Agency) Docket OPPT-2002-
0043. St. Paul, MN:3M, Specialty Materials Markets Group. 
Andersen ME, Butenhoff JL, Chang S-C, Farrar DG, Kennedy 
GL Jr, Lau C, et al. 2008. Perfluoroalkyl acids and related 
chemistries—toxicokinetics and modes of action. Toxicol 
Sci 102:3–14.
Begley TH, Hsu W, Noonan G, Diachenko G. 2008. Migration of 
fluoro  chemical paper additives from food-contact paper 
into foods and food simulants. Food Add Contam 25:384–390.
Benskin JP, De Silva AO, Martin LJ, Arsenault G, McCrindle R, 
Riddell N, et al. 2009. Disposition of perfluorinated acid iso-
mers in Sprague-Dawley rats; part 1: single dose. Environ 
Toxicol Chem 28:542–554.
Butt CM, Muir DCG, Mabury SA. 2010. Biotransformation of 
the 8:2 fluorotelomer acrylate in rainbow trout. I. In vivo 
dietary exposure. Environ Toxicol Chem 29(12):2726–2735. 
Calafat AM, Wong L-Y, Kuklenyik Z, Reidy JA, Needham LL. 
2007. Polyfluoroalkyl chemicals in the U.S. population: data 
from the National Health and Nutrition Examination Survey 
(NHANES) 2003–2004 and comparisons with NHANES 
1999–2000. Environ Health Perspect 115:1596–1602.
Chang S-C, Das K, Ehresman DJ, Ellefson ME, Gorman GS, 
Hart JA, et al. 2008. Comparative pharmacokinetics of 
perfluoro  butyrate in rats, mice, monkeys, and humans and 
relevance to human exposure via drinking water. Toxicol 
Sci 104:40–53.
D’eon JC, Crozier PW, Furdui VI, Reiner EJ, Libelo EL, 
Mabury SA. 2009. Observation of a commercial fluorinated 
material, the polyfluoroalkyl phosphoric acid diesters, 
in human sera, wastewater treatment plant sludge, and 
paper fibers. Environ Sci Technol 43:4589–4594.
D’eon JC, Mabury SA. 2007. Production of perfluorinated car-
boxylic acids (PFCAs) from the biotransformation of poly-
fluoroalkyl phosphate surfactants (PAPS): exploring routes 
of human contamination. Environ Sci Technol 41:4799–4805.
D’eon JC, Mabury SA. 2010. Uptake and elimination of perfluo-
rinated phosphonic acids in the rat. Environ Toxicol Chem 
29:1319–1329.
De Silva AO, Benskin JP, Martin LJ, Arsenault G, McCrindle R, 
Riddell N, et al. 2009. Disposition of perfluorinated acid 
isomers in Sprague-Dawley rats; part 2: subchronic dose. 
Environ Toxicol Chem 28:555–567.
De Silva AO, Mabury SA. 2006. Isomer distribution of perfluoro-
carboxylates in human blood: potential correlation to 
source. Environ Sci Technol 40:2903–2909.
DuPont. 2002. Telomer Research Program Update. Presentation 
to the U.S. EPA, November 25, 2002. Public Docket AR226-
1141. Washington, DC:U.S. Environmental Protection 
Agency Office of Pullution Prevention and Toxics. Available: 
http://www.regulations.gov/#!documentDetail;D=EPA-HQ-
OPPT-2002-0051-0034 [accessed 25 January 2011]. 
Dupont. 2005. DuPont Global PFOA Strategy. Presentation to 
the U.S. EPA, January 31, 2005. Public Docket AR226-1914. 
Washington, DC:U.S. Environmental Protection Agency 
Office of Pullution Prevention and Toxics.
Fasano WJ, Carpenter SC, Gannon SA, Snow TA, Stadler JC, 
Kennedy GL Jr, et al. 2006. Absorption, distribution, metabo-
lism, and elimination of 8–2 fluorotelomer alcohol in the rat. 
Toxicol Sci 91:341–355.
Fromme H, Schlummer M, Möller A, Gruber L, Wolz G, 
Ungewiss J, et al. 2007. Exposure of an adult population 
to perfluorinated substances using duplicate diet portions 
and biomonitoring data. Environ Sci Technol 41:7928–7933.
Fromme H, Tittlemier SA, Völkel W, Wilhelm M, Twardella D. 
2009. Perfluorinated compounds—exposure assessment 
for the general population in western countries. Int J Hyg 
Environ Health 212:239–270.
Hagen DF, Belisle J, Johnson JD, Venkateswarlu P. 1981. 
Characterization of fluorinated metabolites by a gas 
chromatographic-helium microwave plasma detector—
the biotransformation of 1H,1H,2H,2H-perfluorodecanol to 
perfluoro  octanoate. Anal Biochem 118:336–343.
Han X, Yang C-H, Snajdr SI, Nabb DL, Mingoia RT. 2008. Uptake 
of perfluorooctanoate in freshly isolated hepatocytes from 
male and female rats. Toxicol Lett 181:81–86.
Haug LS, Thomsen C, Becher G. 2009. Time trends and the 
influence of age and gender on serum concentrations of 
perfluorinated compounds in archived human samples. 
Environ Sci Technol 43:2131–2136.
Kärrman A, Harada KH, Inoue K, Takasuga T, Ohi E, Koizumi A. 
2009. Relationship between dietary exposure and serum 
perfluoro  chemical (PFC) levels—a case study. Environ Int 
35:712–717.
Kärrman A, Mueller JF, Van Bavel B, Harden F, Toms L-ML, 
Lindström G. 2006. Levels of 12 perfluorinated chemcials in 
pooled Australian serum, collected 2002–2003, in relation to 
age, gender, and region. Environ Sci Technol 40:3742–3748.
Kissa E. 2002. Fluorinated Surfactants. New York:Marcel Dekker.
Lee H, D’eon J, Mabury SA. 2010. Biodegradation of polyfluoro-
alkyl phosphates (PAPs) as a source of perfluorinated acids 
to the environment. Environ Sci Technol 44:3305–3310.
Ohmori K, Kudo N, Katayama K, Kawashima Y. 2003. Comparison 
of the toxicokinetics between perfluoro  carboxylic acids 
with different carbon chain length. Toxicology 184:135–140.
Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, 
Butenhoff JL, et al. 2007. Half-life and serum elimination of 
perfluorooctanesulfonate, perfluorohexanesulfonate, and 
pefluorooctanoate in retired fluorochemical production 
workers. Environ Health Perspect 115:1298–1305.
Olsen GW, Huang H-Y, Helzlsouzer KJ, Hansen KJ, Butenhoff JL, 
Mandel JH. 2005. Historical comparison of perfluorooc-
tanesulfonate, perfluorooctanoate, and other fluorochemi-
cals in human blood. Environ Health Perspect 113:539–545.
Olsen GW, Mair DC, Church TR, Ellefson ME, Reagen WK, 
Boyd TM, et al. 2008. Decline in perfluorooctanesulonate 
and other polyfluoroalkyl chemicals in American Red 
Cross adult blood donors, 2000–2006. Environ Sci Technol 
42:4989–4995.
Ostertag SK, Chan HM, Moisey J, Dabeka R, Tittlemier SA. 
2009. Historic dietary exposure to perfluorooctane sul-
fonate, perfluorinated carboxylates, and fluorotelomer 
unsaturated carboxylates from the consumption of store-
bought and restaurant foods for the Canadian population. 
J Agric Food Chem 57:8534–8544.
Shoeib M, Harner T, Wilford B, Jones KC, Zhu J. 2005. 
Perfluorinated sulfonamides in indoor and outdoor air and 
indoor dust: occurrence, partitioning, and human exposure. 
Environ Sci Technol 39:6599–6606.
Stock NL, Lau FK, Ellis DA, Martin JW, Muir DDC, Mabury SA. 
2004. Polyfluorinated telomer alcohols and sulfonamides 
in the North American troposphere. Environ Sci Technol 
38:991–996.
Trudel D, Horowitz L, Wormuth M, Scheringer M, Cousins IT, 
Hungerbuhler K. 2008. Estimating consumer exposure to 
PFOS and PFOA. Risk Anal 28:251–269.
Vestergren R, Cousins IT. 2009. Tracking the pathways of human 
exposure to perfluoro  carboxylates. Environ Sci Technol 
43:5565–5575.
Vestergren R, Cousins IT, Trudel D, Wormuth M, Scheringer M. 
2008. Estimating the contribution of precursor compounds 
in consumer exposure to PFOS and PFOA. Chemosphere 
73:1617–1624.
Ward KW, Hardy LB, Kehler JR, Azzarano M, Smith BR. 2004. 
Apparent absolute oral bioavailability in excess of 100% 
for a vitronectin receptor antagonist (SB-265123) in rat. II. 
Studies implicating transporter-mediated intestinal secre-
tion. Xenobiotica 34:367–377.
Xu L, Krenitsky DM, Seacat AM, Butenhoff JL, Anders MW. 2004. 
Biotransformation of N-ethyl-N-(2-hydroxyethyl)perfluoro-
octane  sulfonamide by rat liver microsomes, cytosol, and 
slices and by expressed rat and human cytochromes P450. 
Chem Res Toxicol 17:767–775. 
Yamashita N, Kannan K, Taniyasu S, Horii Y, Petrick G, Gamo T. 
2005. A global survey of perfluorinated acids in oceans. 
Mar Pollut Bull 51:658–668.